Abstract
Evidence is accumulating for the early sustained usage of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis. Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998. Postmarketing surveillance, case reports and observational studies have highlighted less common or unexpected adverse events. Therefore, it is appropriate that we review the benefit-risk profile of leflunomide after 10 years of widespread usage. A wide-based search of relevant literature was performed to formulate this assessment.
The improvements in rheumatoid arthritis shown by double-blind, randomized controlled trials (RCTs) of leflunomide have now been shown to be maintained beyond 4 years in open-label extension studies. Leflunomide is comparable to methotrexate, but better than sulfasalazine at 24 months in only one study. However, tolerance in clinical practice research shows higher than expected withdrawal rates due to both toxicity and lack of efficacy when compared with methotrexate and placebo.
Adverse events reported include gastrointestinal upset, hypertension, headache, hepatotoxicity and hair loss, as well as predisposition to infection and peripheral neuropathy. The incidence of gastrointestinal adverse effects for leflunomide is similar to sulfasalazine but higher than those seen with methotrexate. Serious drug-induced hepatotoxicity leading to hospitalization is rare (0.02%), but isolated fatalities from liver failure have been documented. It is considered likely, but not yet proven, that there may be an increased incidence of weight loss and interstitial lung disease with leflunomide.
Leflunomide in combination with methotrexate or sulfasalazine is an effective regimen in RCTs utilizing placebo controls, but more research is needed to confirm its effectiveness in combination with other DMARDs, particularly biologicals.
The active metabolite of leflunomide is teratogenic in animal studies and is also found in breast milk. Therefore, contraception is advised in both males and females of child-bearing potential. There are genetic, pharmacokinetic and biochemical reasons to explain variation in both patient response and adverse event profile. Hence, blood and blood pressure monitoring are recommended and therapeutic drug monitoring should be considered in clinical nonresponders.
Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate. However, adverse effects necessitate frequent monitoring. It should be used with caution in those of child-bearing potential and with pre-existing lung and liver disease.
Similar content being viewed by others
References
Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38(11): 1595–603
Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159(21): 2542–50
Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multi-centre trial. European Leflunomide Study Group. Lancet 1999; 353(9149): 259–66
HMR’s Arava launched in US. Scrip 1998; 2387: 19
HMR’s Arava launched in EU. Scrip 1999; 2471: 22
Ruckermann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998; 273(21): 21682–91
Cherwinski HM, Cohn RG, Cheung P, et al. The immuno-suppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275: 1043–9
Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999; 58(6): 1137–64
Xu X, Blinder L, Shen J, et al. In vivo mechanism by which leflunomide controls lymphoproliferative and auto immune disease in MRL/MpJ-Ipr/Ipr mice. J Immunol 1997; 159: 167–74
Kraan MC, Reece RJ, Barg BE, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomised, double-blind, parallel-design clinical trial in thirty-nine patients at two centres. Arthritis Rheum 2000; 43(8): 1820–30
Litinsrky I, Paran D, Levartovsky D, et al. The effect of leflunomide on clinical parameters and serum levels of IL6, IL10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine 2006; 33(2): 106–10
Cao WW, Kao PN, Aoki Y, et al. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine TGF-B1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 1996; 28: 3079–80
Kraan MC, De Koster BM, Elferink JG, et al. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: finding in prospective randomised double blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43(7): 1488–95
Siesmasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 27(61): 635–42
Siesmasko KF, Chong AS, Jack HM, et al. Inhibition of JAK-3 and Stat 6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IG1 production. J Immunol 1998; 160(15): 1581–8
Weithmann KU, Jescke S, Schlotte V. Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation. Agent Actions 1994; 41: 164–70
Hoechst Marion Rousel. Arava (leflunomide) prescribing information. Kansas City (MO): Hoechst Marion Roussel Inc., 1998 Sep
Hoechst Marion Rousel. Arava: pharmacokinetics. Kansas City (MO): Hoechst Marion Roussel Inc., 1998. (Data on file)
Hoechst Marion Rousel. Arava: washout with cholestyramine and activated charcoal. Kansas City (MO): Hoechst Marion Roussel Inc., 1998. (Data on file)
Siva C, Eisen SA, Shepherd R, et al. Leflunomide use during the first 33 months after Food and Drug Administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum 2003; 42(6): 745–51
Chan V, Charles BG, Tett SE. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Pharm 2005; 60(3): 257–64
Jaimes-Hernandez J, Robles-San Rroman M, Suarez-Otero R, et al. Rheumatoid arthritis treatment weekly leflunomide: an open-label study. J Rheumatol 2004; 31(2): 235–7
Poor G, for the Leflunomide Multinational Study Group and Strand V. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomised trial. Rheumatol 2004; 43: 744–9
Jakez-Ocampo J, Richaud-Patin Y, Simon JA, et al. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint Bone Spine 2002; 69(3): 307–11
Weber W, Harnisch L. Use of a population pharmacokintic model to predict clinical outcome of leflunomide, a new DMARD in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 1997; 40(9): S153
van Roon EN, Jansen TLTA, van der Laar MAFJ, et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 569–74
Kis E, Nagy T, Jani M, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis 2009; 68(7): 1201–7
Hoechst Marion Rousell. Arava: drug interactions. Kansas City (MO): Hoechst Marion Roussel Inc., 1998. (Data on file)
Lim V, Pande I. Leflunomide can potentiate the anticoagulant effects of warfarin [letter]. BMJ 2002; 325: 1333
Wolfe F. The effect of smoking on clinical/laboratory and radiographic status in rheumatoid arthritis. J Rheumatol 2000; 27(3): 630–7
Saag KG, Cerhan JR, Kolluri S, et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997; 56(8): 463–9
Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001 Sep; 44(9): 1984–92
Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulphasalazine. Ann Rheum Dis 2001 Oct; 60(10): 913–23
Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 Jun; 39(6): 655–65
Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol 2003 Jun; 30(6): 1182–90
Wolfe F, Michaud K, Gefeller O, et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48(6): 1530–42
Pincus T, Summey JA, Soraci Jr SA, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum 1983; 26: 1346–53
Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8-item HAQ (DHAQ), and a rescored 20-item HAQ (HAQ20): analyses in 2491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001; 28(5): 982–9
van der Heijde D. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl. 2: 74–8
Sharp JT, Lidsky MD, Collins LC, et al. Methods of scoring the progression of radiographic changes in rheumatoid arthritis, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 706–20
Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977; 18: 481–91
Kalden JR, Schattenkirchner M, Sorensen H, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow up study. Arthritis Rheum 2003 Jun; 48(6): 1513–20
van der Heijde D, Kalden J, Scott D, et al. Long term evaluation of radiographic progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis 2004 Jun; 63(6): 737–9
van Roon EN, Jansen TL, Mourad L, et al. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharm 2004; 57(6): 790–7
Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvements in clinical trials. Ann Rheum Dis 2006; 65: 227–33
Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003; (1): CD002047
McEntegart A. Leflunomide. In: Capell H, Madhok R, McInnes IB, editors. Practical prescribing guidelines in rheumatoid arthritis. Martin Dunitz, 2003: 101–12
Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease modifying medications for rheumatoid arthritis. Ann Int Med 2008; 148(2): 124–34
The European Agency for the Evaluation of Medicinal Products. EMEA public statement on leflunomide (ARAVA): severe and serious hepatic reactions, 12 March 2001 [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Arava/561101en.pdf [Accessed 2009 Sep 22]
Van Roon EN, Jansen TL, Houtman NM, et al. Leflunomide for the treatment of rheumatoid arthrtis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 2004; 27(5): 345–52
Charlatan F. Arthritis drug should be removed from market, says consumer group [letter]. BMJ 2002; 324: 869
Food and Drug Administration, Arthritis Advisory Committee. Briefing information: Arava™ (leflunomide), March 5, 2003 [online]. Available from URL: http://www.fda.gov [Accessed 2009 Jul 30]
Suissa S, Ernst P, Hudson M, et al. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 2004; 117(2): 87–92
Sevilla-Mantila C, Ortega L, Agundez JA, et al. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004; 36(1): 82–4
Tan SC, New LS, Chan EC. Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine. Toxicol Lett 2008; 180(3): 174–81
Tanaka N, Sakahashi H, Sato E, et al. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol 2003; 9(2): 115–8
Jenks KA, Stamp LK, O’Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol 2007; 34(11): 2201–3
Ezanuer RJ, Khan KJ. Pneumocystitis carnii pneumonia associated with leflunomide therapy for rheumatoid arthritis. J Clin Rheum 2002; 8(1): 64–6
Richards BL, Spies J, McGill N, et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J 2007; 37(2): 101–7
Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004; 43(12): 1201–4
Takeishi M, Akiyama Y, Akiba H, et al. Leflunomide-induced acute interstitial pneumonia. J Rheumatol 2005; 32: 1160–3
McCurry J. Japan deaths spark concern over arthritis drug [letter]. Lancet 2004; 363(9407): 461
Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54(5): 1435–9
Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007; 56(6): 2094–6
Kanbe K, Inoue K, Chiba J, et al. The side-effects and efficacy of leflunomide in Japanese patients with rheumatoid arthritis. APLAR J Rheumatol 2005; 8(2): 114–8
Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators’ Group. J Rheumatol Suppl 1998; 53: 27–32
Coblyn JS, Shadick N, Helfgott S. Leflunomide-associated weight loss in rheumatoid arthritis. Arthritis Rheum 2001; 44(5): 1048–51
van Riel PL, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol Suppl 2004; 71: 21–4
Dale J, Alcorn N, Capell H, et al. Combination therapy for rheumatoid arthritis: methotrexate and sulphaslazine together or with other DMARDs. Nat Clin Pract Rheumatol 2007; 3(80): 450–8
Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42(7): 1322–8
Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137(9): 726–33
Kremer J, Genovese M, Cannon GW, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004; 31(8): 1521–31
Cohen S, Schiff M, Weaver A, et al. Leflunomide (LEF) as an initial therapy with methotrexate (MTX) added for rheumatoid arthritis patients with active disease [abstract]. Arthritis Rheum 2002; 46 Suppl.: S352
Dougados M, Emery P, Lemmel EM, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003; 30(12): 2572–9
Hansen KE, Cush J, Singhal A, et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum 2004; 51(2): 228–32
Patel S, Bergen W, Kraemer A, et al. Efficacy and safety of Remicade (infliximab) plus Arava (leflunomide) in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001; 44 Suppl.: S84
Perdriger A, Combe B, Kuntz JL, et al. A French multi-centre retrospective study on the efficacy and safety of leflunomide in association with DMARDs other than methotrexate [abstract]. Ann Rheum Dis 2004; 50 Suppl.: 488
Godinho F, Godfrin B, El Mahou S, et al. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22(3): 328–30
Ortiz Garcia AM, Gonzalez-Alvaro I, Rosello Pardo R, et al. Effectiveness and safety of infliximab combined with leflunomide in chronic polyarthritis [letter]. Clin Exp Rheumatol 2004; 22(6): 790
Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (Oxford) 2002; 41(6): 631–7
Struppler CI, Theis W, Schattenkirchner M, et al. Safety and efficacy of leflunomide and infliximab in rheumatoid arthritis (RA) [abstract]. Ann Rheum Dis 2002; 61: S388
Bingham SJ, Buch MH, Kerr MA, et al. Induction of anti-nuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum 2004; 50(12): 4072–3
Flendrie M, Creemers MC, Welsing PM, et al. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford) 2005; 44(4): 472–8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alcorn, N., Saunders, S. & Madhok, R. Benefit-Risk Assessment of Leflunomide. Drug-Safety 32, 1123–1134 (2009). https://doi.org/10.2165/11316650-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11316650-000000000-00000